Short Interest in NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Declines By 71.0%

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) saw a large decline in short interest in the month of April. As of April 15th, there was short interest totalling 208,100 shares, a decline of 71.0% from the March 31st total of 718,800 shares. Currently, 0.6% of the company’s shares are short sold. Based on an average daily trading volume, of 3,490,000 shares, the days-to-cover ratio is currently 0.1 days.

NovaBay Pharmaceuticals Stock Performance

Shares of NYSEAMERICAN:NBY remained flat at $0.08 during trading on Thursday. 491,539 shares of the stock traded hands, compared to its average volume of 3,361,271. NovaBay Pharmaceuticals has a 12 month low of $0.07 and a 12 month high of $1.42. The firm has a market cap of $324,170.00, a PE ratio of -0.01 and a beta of 2.82.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) last issued its quarterly earnings data on Tuesday, March 26th. The biopharmaceutical company reported ($0.95) earnings per share (EPS) for the quarter. The firm had revenue of $3.73 million for the quarter. NovaBay Pharmaceuticals had a negative net margin of 79.70% and a negative return on equity of 146.20%. On average, sell-side analysts anticipate that NovaBay Pharmaceuticals will post -2.54 EPS for the current year.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.